Stem Cell Clinic vs. Clinical Trial: What's the Real Difference?

Two very different things get described in almost identical language: "stem cell clinical trial." One is a registered, FDA-overseen study with informed consent standards, independent ethics review, and results that are (at least in principle) publicly tracked. The other is a marketing category — a direct-to-consumer procedure, typically using the patient's own fat or bone marrow tissue, sold outside any FDA-approved pathway, often same-day, and paid for entirely out of pocket. The two are frequently confused because clinics that sell the second thing routinely borrow the vocabulary of the first, including registering on ClinicalTrials.gov itself. The FDA has published specific consumer guidance warning that this happens, and this article walks through what actually separates a real trial from a lookalike.

The Core Legal Distinction

A legitimate clinical trial testing a stem cell or regenerative product operates under an FDA Investigational New Drug (IND) application, which the sponsor must have before legally administering an unapproved biologic product to human subjects. The study protocol is reviewed by an Institutional Review Board (IRB) — an independent committee whose job, per FDA guidance, is to "approve, require modifications in (to secure approval), or disapprove research" and confirm that the risks to participants are justified and that consent documents are honest and understandable. Participants sign a formal informed consent document describing the investigational nature of the product, known and unknown risks, and their right to withdraw. In most legitimate trials, the sponsor covers the cost of the investigational product, and some trials compensate participants for time and travel; charging patients directly is something the FDA generally does not allow except in narrow, disclosed circumstances.

A direct-to-consumer stem cell clinic offering, by contrast, typically operates entirely outside this structure. The "product" — most often stromal vascular fraction from a patient's own liposuctioned fat, or a bone-marrow concentrate — is manufactured chairside without an IND, marketed as a treatment for conditions ranging from osteoarthritis to autism to ALS, and sold directly to the patient, who pays out of pocket. There is no independent IRB reviewing the protocol, no standardized informed consent process, and no requirement to report outcomes anywhere. As of 2026, the FDA has not approved any stem cell or stromal vascular fraction product for orthopedic, neurological, or general regenerative use, so any clinic offering these products for such conditions is, by definition, offering something outside the approved system.

The Growth of the Direct-to-Consumer Market

This is not a fringe issue. A 2021 study published in Cell Stem Cell by bioethics researcher Leigh Turner and colleagues found that the number of U.S. businesses selling unlicensed, non-FDA-approved stem cell products grew roughly four-fold in five years — from about 351 businesses operating 570 clinics in 2016 to approximately 1,480 businesses operating 2,754 clinics by 2021, with California, Texas, and Florida having the largest concentrations. The same research found patients paying anywhere from roughly $1,200 to $28,000 per treatment, averaging around $5,100 — cash payments that would be unusual, and in many cases prohibited, within an actual FDA-regulated trial.

Why "It's a Clinical Trial" Doesn't Always Mean What Patients Think

This is the crux of the confusion, and the FDA has addressed it directly. In its consumer guidance on regenerative medicine therapies, the agency states plainly that "patients and consumers are being referred to clinicaltrials.gov, or are told that a product is registered with FDA, as a way to suggest that the products being offered are in compliance with FDA laws and regulations. This is often false," adding that "the inclusion of a product in the clinicaltrials.gov database or the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed."

Part of why this loophole exists is that ClinicalTrials.gov accepts listings for observational studies, not just interventional trials with FDA oversight, and the registration bar for an observational listing is much lower — it does not require IND or IDE approval. Turner has documented what he calls "pay-to-participate" listings: studies where patients are charged to enroll, some enrolling well over 100 participants, with at least one network-affiliated listing estimating enrollment in the thousands. Stem cell scientist Jeanne Loring has described the practice bluntly, saying such clinics are "using the site as a marketing tool, just like newspaper ads." In other words, a clinic can technically be telling the truth when it says "we're listed on ClinicalTrials.gov" while still not offering anything resembling a controlled, IRB-overseen, FDA-regulated trial. The listing itself is not a stamp of legitimacy — it is closer to a directory entry.

"Patient-Funded Registries" Are Not Clinical Trials

A related and commonly misunderstood category is the "patient-funded registry" or observational registry, which some clinics run and describe using trial-adjacent language ("enrolled in our study," "part of our registry," "outcomes are tracked"). These are fundamentally different from controlled clinical trials: there is typically no control group, no randomization, no blinding, no independent statistical monitoring, and — critically — the patient is paying for the treatment itself, with the "registry" functioning as an after-the-fact data collection exercise rather than a scientific test of safety or efficacy. Registries can have legitimate scientific value when run rigorously and transparently, but a patient-funded registry attached to a commercial treatment is not evidence that the treatment works, and it is not the same regulatory or ethical category as a randomized controlled trial reviewed by an IRB under an active IND.

How to Actually Check

The most direct way to verify a specific trial is to look it up on ClinicalTrials.gov and read past the title. Key things to check: whether the study is interventional (a real trial testing an intervention) or observational (often just data collection); whether it lists an active IND or IDE number; who the sponsor is and whether it's an academic medical center, NIH-funded consortium, or pharmaceutical/biotech sponsor versus a private clinic network; whether the study has a control or comparator arm; and whether the "Eligibility" section mentions a fee to participate, which is unusual for a legitimate interventional trial. A clinic's own website describing something as "clinical research" or "part of our trial" is not verification — the listing itself, read carefully, is.

Bottom Line

The single most useful question a patient can ask a clinic is not "is this a clinical trial?" but "can you show me the FDA IND number and the ClinicalTrials.gov listing, and can I read the informed consent document before I pay anything?" A real trial will have documentation ready and typically will not ask for payment for the investigational product itself. A same-day procedure sold under trial-like language, funded entirely by the patient, with no IRB and no published outcomes, is a commercial offering — not research — regardless of what it's called on a brochure or even on a registry listing. Given that the FDA has not approved stem cell or stromal vascular fraction products for most conditions currently being marketed, and that the direct-to-consumer market has expanded rapidly with reported patient costs averaging around $5,100 per treatment, the burden of verification falls on the patient, and ClinicalTrials.gov, read carefully rather than cited as a credential, is the best publicly available tool to do it.